Table 1. The treatment schedule, acceptance, completion and adverse event rates of isoniazid (INH) and INH plus rifapentine (3HP).
| Drug | Dosing schedule | Observed? | Acceptance rate | Completion rate | Rate of systemic drug reactions | Hepatotoxicity |
|---|---|---|---|---|---|---|
| Isoniazid (INH9) | Daily dose for 9 months | No. Self-administered | 62%1 (26) | 18-69% (27-30) | 0.4% (31) | 2.7% (20) |
| INH+ rifapentine (3HP)2 |
Weekly dose for 12 weeks | Yes. Directly observed treatment. | 60% (27) | 65%–95% (18,19,27-30) | 3.5% (31) | 0.4% (20) |
1 Some patients represented in this estimate were offered INH for six or 12 months rather than nine months 2 Note: The 3HP treatment regime is not yet authorized for use in Canada